Vortex Keratopathy in a Patient Receiving Vandetanib for Non-small Cell Lung Cancer

Overview

Journal Korean J Ophthalmol

Specialty Ophthalmology

Date 2011 Oct 7

PMID 21976946

Citations 11

Authors

Jeeyun Ahn

Won Ryang Wee

Jin Hak Lee

Joon Young Hyon

Affiliations

Soon will be listed here.

Abstract

We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.

Citing Articles

Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report.

Xiang X, Lin W, Guan X, Zhou B, Yuan Y, Silva D Transl Cancer Res. 2024; 13(5):2571-2579.

PMID: 38881937 PMC: 11170519. DOI: 10.21037/tcr-23-1952.

Ocular Surface Side Effects of Novel Anticancer Drugs.

Vitiello L, Lixi F, Coco G, Giannaccare G Cancers (Basel). 2024; 16(2).

PMID: 38254833 PMC: 10814578. DOI: 10.3390/cancers16020344.

Drug-induced corneal deposits: an up-to-date review.

Sahyoun J, Sabeti S, Robert M BMJ Open Ophthalmol. 2022; 7(1):e000943.

PMID: 35415268 PMC: 8961126. DOI: 10.1136/bmjophth-2021-000943.

Ocular Toxicity of Targeted Anticancer Agents.

Fortes B, Tailor P, Dalvin L Drugs. 2021; 81(7):771-823.

PMID: 33788182 DOI: 10.1007/s40265-021-01507-z.

Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study.

Parrozzani R, Lombardi G, Midena E, Londei D, Padovan M, Marchione G Front Oncol. 2020; 10:593461.

PMID: 33154952 PMC: 7591744. DOI: 10.3389/fonc.2020.593461.

References

Pallis A, Serfass L, Dziadziusko R, Van Meerbeeck J, Fennell D, Lacombe D . Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer. 2009; 45(14):2473-87. DOI: 10.1016/j.ejca.2009.06.005. View

Kinoshita S . Clinical application of epidermal growth factor in ocular surface disorders. J Dermatol. 1992; 19(11):680-3. DOI: 10.1111/j.1346-8138.1992.tb03759.x. View

Ciardiello F, Tortora G . EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358(11):1160-74. DOI: 10.1056/NEJMra0707704. View

Yeh S, Fine H, Smith J . Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. Cornea. 2009; 28(6):699-702. DOI: 10.1097/ICO.0b013e3181922146. View

Nakamura Y, Sotozono C, Kinoshita S . The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res. 2001; 72(5):511-7. DOI: 10.1006/exer.2000.0979. View

Cohen S, ELLIOTT G . The stimulation of epidermal keratinization by a protein isolated from the submaxillary gland of the mouse. J Invest Dermatol. 1963; 40:1-5. DOI: 10.1038/jid.1963.1. View

Tullo A, Esmaeli B, Murray P, Bristow E, Forsythe B, Faulkner K . Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (Lond). 2005; 19(7):729-38. DOI: 10.1038/sj.eye.6701630. View

Frati L, Daniele S, Delogu A, Covelli I . Selective binding of the epidermal growth factor and its specific effects on the epithelial cells of the cornea. Exp Eye Res. 1972; 14(2):135-41. DOI: 10.1016/0014-4835(72)90059-0. View

Yano S, Kondo K, Yamaguchi M, Richmond G, Hutchison M, Wakeling A . Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res. 2003; 23(5A):3639-50. View

10.

Kasayama S, Ohba Y, Oka T . Expression of the epidermal growth factor gene in mouse lachrymal gland: comparison with that in the submandibular gland and kidney. J Mol Endocrinol. 1990; 4(1):31-6. DOI: 10.1677/jme.0.0040031. View

11.

DAmico D, Kenyon K . Drug-induced lipidoses of the cornea and conjunctiva. Int Ophthalmol. 1981; 4(1-2):67-76. DOI: 10.1007/BF00139581. View

12.

Wilson S, Liang Q, Kim W . Lacrimal gland HGF, KGF, and EGF mRNA levels increase after corneal epithelial wounding. Invest Ophthalmol Vis Sci. 1999; 40(10):2185-90. View

13.

Wilson S, He Y, Weng J, Zieske J, Jester J, Schultz G . Effect of epidermal growth factor, hepatocyte growth factor, and keratinocyte growth factor, on proliferation, motility and differentiation of human corneal epithelial cells. Exp Eye Res. 1994; 59(6):665-78. DOI: 10.1006/exer.1994.1152. View

14.

Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell. 2000; 103(2):211-25. DOI: 10.1016/s0092-8674(00)00114-8. View

15.

Zhang G, Basti S, Jampol L . Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature. Cornea. 2007; 26(7):858-60. DOI: 10.1097/ICO.0b013e318064584a. View

16.

Hollander D, Aldave A . Drug-induced corneal complications. Curr Opin Ophthalmol. 2004; 15(6):541-8. DOI: 10.1097/01.icu.0000143688.45232.15. View

17.

LULLMANN H, Lullmann-Rauch R, Wassermann O . Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit Rev Toxicol. 1975; 4(2):185-218. DOI: 10.1080/10408447509164014. View

18.

Cohen S . The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol. 1965; 12(3):394-407. DOI: 10.1016/0012-1606(65)90005-9. View

19.

Stein C, LaRocca R, Thomas R, McAtee N, Myers C . Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol. 1989; 7(4):499-508. DOI: 10.1200/JCO.1989.7.4.499. View

20.

Savage Jr C, Cohen S . Proliferation of corneal epithelium induced by epidermal growth factor. Exp Eye Res. 1973; 15(3):361-6. DOI: 10.1016/0014-4835(73)90151-6. View